About ARS Pharmaceuticals, Inc.
Patients are the central focus in every aspect of what we do. Early intervention is key to prevent severe allergic reactions that could lead to anaphylaxis. Patients and families at risk deserve a treatment they can trust to better protect themselves.
Our science is backed up by best-in-industry management, scientific advisory board and investors.
According to published studies, up to 5.3 million people in the United States are at risk of having an anaphylaxis reaction that may warrant immediate medical treatment, with more than 200,000 emergency room visits due to severe reactions from food allergies reported annually.
Many people at risk are reluctant to carry bulky auto-injectors with them at all times. In addition, there is a fear of needles and a hesitation and stigma to use an auto-injector in public to treat the allergic reaction. In addition, for a parent or guardian, injecting a child can be traumatic. Delaying treatment can result in trips to the emergency room.
ARS Pharmaceuticals is committed to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions from food, medications and insect bites that could lead to life-threatening anaphylaxis.
We are developing ARS-1, an intranasal epinephrine spray with a unique absorption technology that is user-friendly, needle-free, reliable, easily portable and convenient to carry in a pocket or purse anytime, anywhere.
ARS-1 is uniquely formulated with Intravail®, an absorption enhancing technology, that has demonstrated a comparable rate of epinephrine absorption to intramuscular injection.
Based on the outcome from our pilot studies, we believe this could potentially be a more reliable and accurate way to deliver epinephrine.
ARS-1 may also enable people to easily deliver epinephrine in emergency situations more rapidly, and with less hesitation, at the onset of a severe allergic reaction.